High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma

BACKGROUND: Adaptive resistance and side effects of sorafenib treatment result in unsatisfied survival of patients with hepatocellular carcinoma (HCC). Palmitoyl-protein thioesterase 1 (PPT1) plays a critical role in progression of various cancers. However, its role on prognosis and immune infiltrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianjun, Su, Zhe, Cheng, Xiang, Hu, Shaobo, Wang, Wenjie, Zou, Tianhao, Zhou, Xing, Song, Zifang, Xia, Yun, Gao, Yang, Zheng, Qichang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917761/
https://www.ncbi.nlm.nih.gov/pubmed/35277179
http://dx.doi.org/10.1186/s12935-022-02508-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917761/
https://www.ncbi.nlm.nih.gov/pubmed/35277179
http://dx.doi.org/10.1186/s12935-022-02508-y

Ejemplares similares